Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PTGX | US
-0.61
-1.36%
Healthcare
Biotechnology
30/06/2024
04/10/2024
44.37
44.63
45.24
44.16
Protagonist Therapeutics Inc. a biopharmaceutical company develops peptide-based drugs for hematology and blood disorders and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300) an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis iron overload and other blood disorders; and JNJ-2113 an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943 an orally delivered gut-restricted alpha 4 beta 7 specific integrin antagonist which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech Inc. Protagonist Therapeutics Inc. was incorporated in 2006 and is headquartered in Newark California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.2%1 month
37.6%3 months
41.9%6 months
49.0%16.38
25.64
4.85
0.02
0.02
13.31
6.49
-
153.21M
2.61B
2.61B
-
-930.96
-
-100.00
40.69
5.58
5.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.44
Range1M
7.12
Range3M
15.50
Rel. volume
0.43
Price X volume
13.91M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 13.31 | 0.76 | Expensive |
Ent. to Revenue | 6.49 | 3,674.48 | Cheaper |
PE Ratio | 16.38 | 38.01 | Cheaper |
Price to Book | 4.85 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 41.91 | 74.67 | Lower Risk |
Debt to Equity | 0.02 | -1.82 | Expensive |
Debt to Assets | 0.02 | 0.26 | Cheaper |
Market Cap | 2.61B | 3.73B | Emerging |